Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05692596 · ClinicalTrials.gov registry record
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
A clinical trial of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- 317
- Enrollment target
- 1
- Study location
NCT05692596 is a study of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 317 participants, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05692596, a study of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 317 participants
- Enrollment target
- 1
- Study location
Study Summary
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05692596
The ClinicalTrials.gov registry entry for NCT05692596 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (47% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT05692596 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05692596 about?
NCT05692596 is a clinical study titled "The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics". The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
What is the current status of trial NCT05692596?
This trial is currently active not recruiting. The enrollment target is 317 participants. The study started on 2022-10-06. Estimated completion is 2026-07.
What conditions does trial NCT05692596 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, Lynch Syndrome, Pancreatic Cyst, BRCA Mutation.
What interventions are being tested in trial NCT05692596?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT05692596?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05692596 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.